Skip to main content

Why PHARMORIS

Move beyond passive analysis without replacing professional judgement

PHARMORIS is intended to address the gap between a medicines opportunity being identified and an accountable, governed decision being carried through to review.

Request PHARMORIS demoExplore the governed workflow
Problem | Evidence does not always become owned actionProduct intent | Governed executionBoundary | Professional judgement is not replaced

After analysis

An opportunity still needs an owner, a gate and a route.

Medicines teams can have evidence without a reliable way to coordinate the decision that follows.

PHARMORIS is intended to make ownership, evidence completeness, blockers and review states visible inside one governed workflow.

01

Identify

Link the opportunity to an approved source and its provenance.

02

Assign

Make the accountable owner and required reviewers explicit.

03

Progress

Track activity and blockers without turning a forecast into a result.

Product difference

A workflow for governed execution, not a claim of autonomous intelligence.

PHARMORIS is designed around explicit human triage, decision gates and review. The product does not authorise prescribing or clinical decisions.

Human decision requiredProceed only inside an evidenced and governed scope.
01

Source linked

A signal should retain the evidence and rights needed to understand its basis.

Doctrine
02

Human governed

Authorised people decide whether an ActionCase progresses.

Boundary
03

Reviewable

The record should show decisions, changes, blockers and closure.

Doctrine

Lead value measure

Measure governed execution before forecast value.

The lead operating measure is governed execution rate: the proportion of validated opportunities that receive an accountable owner, pass the required gates and reach an evidenced deployment or closure state.

Realised value should be reported only where it is independently evidenced.

01

Decision cycle

Understand how long a justified case takes to reach the required gate.

02

Evidence completeness

Make missing provenance, review material and decision context visible.

03

Blocker age

Expose unresolved dependencies that prevent a governed next step.

04

Audit completeness

Retain the record required to explain the final state.

Classified public record

Inspect related publisher records

MEDICINES ANALYSIS + EXECUTION

You can identify the opportunity and still lose it in delivery.

Explore the financial, operational and governance questions that shaped PHARMORIS. Then check the product’s dated status before treating the model as implemented.

  1. PharmaphorumContributed analysis

    Approval is not access: Pilots' real test is implementation

    In pharmaphorum, Varun Sharma argues that medicines access pilots should measure the full chain from recommendation to funded delivery and outcomes.

    Read the implementation argument
  2. AI Ethics Now / University of Warwick IATLPodcast appearance

    AI and Accountability: When Does a Suggestion Become a Decision?

    Varun Sharma joins AI Ethics Now to examine false confidence, human responsibility and the point where AI assisted suggestions become accountable decisions.

    Hear the human accountability discussion
  3. NEUVIOR Founder ReflectionsNEUVIOR analysis

    After NICE: making medicines access operational

    A recommendation can clarify what should be available. You still need an accountable route from evidence to a local decision, delivery and review.

    Map the work after a medicines recommendation
Explore every medicines analysis

NEUVIOR Insights and After Publication reflections are company or founder analysis. Publisher records evidence publication, not endorsement, adoption, product readiness, savings or clinical outcomes.

Make the next step useful

Bring the problem that needs a clearer decision.

Tell us what is stuck, what decision you need to make and what a better outcome would change. We will connect you to the most relevant NEUVIOR, PHARMORIS, media or investor route.

Request PHARMORIS demoSpeak with NEUVIOR

QUESTIONS · ANSWERED DIRECTLY

The useful answers, in one place.

Browse every question
01What problem does PHARMORIS address?

Medicines teams can identify an opportunity yet still lack a consistent way to connect the evidence to a decision, accountable owner, delivery tasks, blockers and a reviewed result. PHARMORIS is being built for that operational gap.

02Who is PHARMORIS intended for?

PHARMORIS is intended for authorised medicines, pharmacy, finance, procurement and operational teams working inside responsible healthcare institutions. Scope and deployment requirements must be agreed for each organisation.

03Does PHARMORIS replace professional judgement?

No. PHARMORIS is designed to structure evidence and accountable work while keeping professional and institutional decisions with authorised people.

04What is an ActionCase?

An ActionCase is the governed unit of work at the centre of PHARMORIS. It can hold the evidence basis, scope, owner, decisions, tasks, blockers and review record for a medicine opportunity.

05Is PHARMORIS ready for production or deployed?

PHARMORIS is under controlled development and should not be interpreted as a live, adopted or clinically approved product unless a current, specific deployment record says otherwise.

06Does the public demonstration use patient data?

No. Public and representative demonstrations are designed without live data that identifies patients. Any future institutional data scope would require separate governance, security and contractual controls.